Todd Brady is the Director of Finance and Investments at Brace Pharma Capital. He also serves as a director for Brace portfolio companies GeNO LLC, Avidity Biosciences and Tyrogenex, and formerly served as a board observer for Miragen Therapeutics. Todd has an extensive and diverse background in Capital Markets, working in equity research, asset management, private equity and corporate banking over the duration of his career. Todd has a Masters of Business Administration from the Schulich School of Business (York University) and is a Chartered Financial Analyst (CFA).

Alan joined Polaris Partners in 2002 and serves as an entrepreneur partner. In this role, he focuses on building and investing in healthcare companies.

He has served as founder, chairman, and/or CEO in building eight Polaris companies. His current and past portfolio include: Momenta Pharmaceuticals, Visterra, Navitor Pharmaceuticals, Dyno Therapeutics, Pandion Therapeutics, KSQ Therapeutics, T2 Biosystems, Ocular Therapeutix, Sirtris Pharmaceuticals, Adnexus Therapeutics, Arsia Therapeutics, Seventh Sense Biosystems, Cerulean Pharma, and XTuit Pharmaceuticals. From 2002 to 2006, Alan was president and CEO of Momenta Pharmaceuticals (NASDAQ: MNTA). He joined Momenta as the fifth employee and built it into a public company, creating an advanced and diversified pipeline, entering into two strategic collaborations with Novartis and raising $275 million. The first product from Momenta’s pipeline achieved over $1B during its first year of sales.

Prior to Polaris, Alan was senior vice president of global corporate development at Millennium Pharmaceuticals, where he was responsible for leading Millennium’s strategic partnering, mergers and acquisitions, and licensing activities, generating over $2B in partner funding and acquiring 19 development stage products. Among these products was Velcade®, which became the main basis of the company’s $9B acquisition by Takeda. Before joining Millennium, Alan was a marketing executive at DuPont-Merck and a consultant with the Boston Consulting Group and Arthur D. Little.

Alan received Ernst & Young’s Entrepreneur of the Year award for New England and is an Always-On Venture Capital 100 recipient. His current and former non-profit positions include: selection committee for the Harvard Life Lab, expert-in-residence at the Harvard School of Engineering, board member of the Boston Children’s Hospital Trust, founder and vice chair of the Autism Consortium, and president of the board of Gann Academy.

Alan earned a BA in biology, summa cum laude, from Harvard College, an MA in cellular and developmental biology from Harvard Graduate School of Arts & Sciences, and an MBA, with honors, from Harvard Business School. He also spent two years studying towards an MD at Harvard Medical School.

Mr. Creecy is the Chief Executive Officer and a Director of Remeditex Ventures, LLC, a biomedical investment company that seeks to build a robust biomedical portfolio through investments in early-stage university projects and start-up companies within the biomedical industry. Prior to joining Remeditex Mr. Creecy served as President and Chief Executive Officer of Hunt Petroleum Corporation, an Oil and Gas Exploration and Development Company with operations located worldwide. Before Hunt Petroleum he was the Chief Operating Officer of the Hodges Companies, Inc. a closely held private investment entity holding primarily real estate, oil and gas, and agricultural investments.

For more than 30 years Mr. Creecy has served in various board positions within the All Saints Health System in Ft. Worth, Texas now a part of the Baylor Scott and White System. He is currently Chairman of the Board of the Baylor Scott White All Saints Medical Center in Fort Worth. In addition, he has served on the university hospital boards affiliated with the UT Southwestern Medical Center in Dallas, Texas and has been a board member of the Baylor Research Institute located in Dallas, Texas. Mr. Creecy has also served on various boards of multiple early stage biomedical companies in which Remeditex Ventures has invested.

Mr. Creecy is a graduate of Texas Tech University with a Bachelor’s Degree in Accounting and holds a Master’s of Science Degree in Accounting from the University of North Texas. He is a former Certified Public Accountant and currently serves as a member of other various business and civic organizations.

Rajeev joined SR One in 2004 and is an alum of the Kauffman Fellows Program. His prior and current investments include Adheron, iPierian, True North, Propeller Health, Concert Pharmaceuticals, CyDex Pharmaceuticals, NeuroTherapeutics Pharma, Tranquis Therapeutics, IlluminOss Medical, and Avhana Health. Rajeev also spent time with GSK’s competitive excellence group, where he worked on company-wide strategic projects and operational projects. Prior to SR One, Rajeev worked at Genentech, where his role included technology and clinical development, and at Bio-Rad Laboratories in a product development role. In addition, Rajeev has worked in business development at Genome Therapeutics and was a co-founder of Unimicro Technologies.

Rajeev received his BA in chemistry and mathematics from Knox College, his MBA from the Wharton School of the University of Pennsylvania, and his PhD in chemistry from Stanford University.

Jack A. Khattar is the founder of Supernus Pharmaceuticals and has served as President, Chief Executive Officer and Secretary, and a Director since 2005. From 1999 to 2005, he served in various positions during that time as a board member, President, and Chief Executive Officer of Shire laboratories Inc., the drug delivery subsidiary of Shire plc. Prior to that, Jack served as an executive officer and the chairman of the management committee at CIMA Labs Inc. (CIMA), a drug delivery company where he was also responsible for business development, corporate alliances, and strategic planning. Prior to joining CIMA in 1995, he held several marketing and business development positions at Merck & Co., Novartis, Playtex, and Kodak in various locations, including the United States, Europe, and the Middle East. Jack served on the board of Rockville Economic Development, Inc. from 2003 until 2013, and Prevacus, Inc. from 2015 until 2020. He currently serves on the advisory board of New Rhein Healthcare, a private equity firm, and as Chairman of the board of directors of scPharmaceuticals, a publicly traded pharmaceutical company.

Jack received a BBA from American University of Beirut and an MBA from the Wharton School of the University of Pennsylvania.

Marian Nakada has almost 30 years of experience in the pharmaceutical industry, starting her career at the laboratory bench at Centocor and moving to a research leadership role before Centocor’s acquisition by Johnson & Johnson in 1999.

She transitioned to Janssen Business Development where she executed deals to support the expansion of the Biologics portfolio. She joined JJDC, Johnson & Johnson’s corporate venture group, in 2013 and some of her investments include Padlock Therapeutics, CoStim Pharmaceuticals, and Vedanta Biosciences. She is passionate about leveraging Johnson & Johnson’s capabilities to help her portfolio companies succeed. Marian has a B.A. in Biology from Harvard College and a Ph.D. in Pharmacology from the University of Pennsylvania. She is currently on the Boards of Navitor Pharmaceuticals, Twenty-eight Seven Therapeutics, Ribon Therapeutics, Artizan Biosciences as well as the New England Venture Capital Association where she is working to champion change as an active contributor to its Diversity & Inclusion Committee.

Dr. George P. Vlasuk is a scientifically trained executive with nearly 40 years of leadership experience in drug discovery and development at small and large biotechnology and pharmaceutical companies.

George was previously President, CEO, and CSO of Navitor Pharmaceuticals, Inc., and currently serves as a board member and consultant. He also serves on the Boards of Nimbus Therapeutics and Riparian Pharmaceuticals as well as a consultant and scientific advisor to several biopharmaceutical companies. Before joining Navitor, George served as CEO of Sirtris, a GlaxoSmithKline Company. Prior to Sirtris, he was Vice President, Metabolic Disease and Hemophilia Research, at Wyeth Pharmaceuticals. Dr. Vlasuk also previously served as Chief Scientific Officer and Executive Vice President of Research and Development at Corvas International, prior to the merger of Corvas and Dendreon Corporation. Earlier in his career, George led a research team at Merck and Co., and was responsible for multiple discovery programs in the field of cardiovascular medicine. He is the author of more than 100 peer-reviewed scientific publications, book chapters, and reviews, and 38 issued U.S. and foreign patents.